FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154798443> ?p ?o ?g. }

• W2154798443 endingPage "12" @default.
• W2154798443 startingPage "12" @default.
• W2154798443 abstract "The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARgamma) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care.Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed.Systolic (SBP) and diastolic (DBP) blood pressure reduction, response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs).After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE.There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile." @default.
• W2154798443 created "2016-06-24" @default.
• W2154798443 creator A5002019738 @default.
• W2154798443 creator A5005031786 @default.
• W2154798443 creator A5014306268 @default.
• W2154798443 creator A5052836637 @default.
• W2154798443 creator A5078953106 @default.
• W2154798443 date "2007-01-01" @default.
• W2154798443 modified "2023-10-04" @default.
• W2154798443 title "Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients" @default.
• W2154798443 cites W1580457945 @default.
• W2154798443 cites W1936322262 @default.
• W2154798443 cites W1971638152 @default.
• W2154798443 cites W197378054 @default.
• W2154798443 cites W1986349550 @default.
• W2154798443 cites W2005267351 @default.
• W2154798443 cites W2019535404 @default.
• W2154798443 cites W2026664265 @default.
• W2154798443 cites W2030338284 @default.
• W2154798443 cites W2044231539 @default.
• W2154798443 cites W2048748448 @default.
• W2154798443 cites W2048780387 @default.
• W2154798443 cites W2060449981 @default.
• W2154798443 cites W2077232388 @default.
• W2154798443 cites W2083435278 @default.
• W2154798443 cites W2095637793 @default.
• W2154798443 cites W2103714496 @default.
• W2154798443 cites W2113101845 @default.
• W2154798443 cites W2121741612 @default.
• W2154798443 cites W2129697991 @default.
• W2154798443 cites W2129751032 @default.
• W2154798443 cites W2133217116 @default.
• W2154798443 cites W2135178747 @default.
• W2154798443 cites W2145017951 @default.
• W2154798443 cites W2147525905 @default.
• W2154798443 cites W2154570146 @default.
• W2154798443 cites W2156783035 @default.
• W2154798443 cites W2162231109 @default.
• W2154798443 cites W2162506832 @default.
• W2154798443 cites W2164310769 @default.
• W2154798443 cites W2169121622 @default.
• W2154798443 cites W2319983832 @default.
• W2154798443 cites W2475261460 @default.
• W2154798443 cites W2562329777 @default.
• W2154798443 cites W4230870013 @default.
• W2154798443 cites W4300047977 @default.
• W2154798443 cites W91098912 @default.
• W2154798443 doi "https://doi.org/10.1186/1475-2840-6-12" @default.
• W2154798443 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1853076" @default.
• W2154798443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17407587" @default.
• W2154798443 hasPublicationYear "2007" @default.
• W2154798443 type Work @default.
• W2154798443 sameAs 2154798443 @default.
• W2154798443 citedByCount "83" @default.
• W2154798443 countsByYear W21547984432012 @default.
• W2154798443 countsByYear W21547984432013 @default.
• W2154798443 countsByYear W21547984432014 @default.
• W2154798443 countsByYear W21547984432015 @default.
• W2154798443 countsByYear W21547984432016 @default.
• W2154798443 countsByYear W21547984432017 @default.
• W2154798443 countsByYear W21547984432018 @default.
• W2154798443 countsByYear W21547984432019 @default.
• W2154798443 countsByYear W21547984432020 @default.
• W2154798443 countsByYear W21547984432021 @default.
• W2154798443 countsByYear W21547984432022 @default.
• W2154798443 crossrefType "journal-article" @default.
• W2154798443 hasAuthorship W2154798443A5002019738 @default.
• W2154798443 hasAuthorship W2154798443A5005031786 @default.
• W2154798443 hasAuthorship W2154798443A5014306268 @default.
• W2154798443 hasAuthorship W2154798443A5052836637 @default.
• W2154798443 hasAuthorship W2154798443A5078953106 @default.
• W2154798443 hasBestOaLocation W21547984431 @default.
• W2154798443 hasConcept C126322002 @default.
• W2154798443 hasConcept C134018914 @default.
• W2154798443 hasConcept C164705383 @default.
• W2154798443 hasConcept C188816634 @default.
• W2154798443 hasConcept C198710026 @default.
• W2154798443 hasConcept C2777693730 @default.
• W2154798443 hasConcept C2778402494 @default.
• W2154798443 hasConcept C2779838083 @default.
• W2154798443 hasConcept C2780259554 @default.
• W2154798443 hasConcept C2780578515 @default.
• W2154798443 hasConcept C511355011 @default.
• W2154798443 hasConcept C555293320 @default.
• W2154798443 hasConcept C71924100 @default.
• W2154798443 hasConcept C84393581 @default.
• W2154798443 hasConceptScore W2154798443C126322002 @default.
• W2154798443 hasConceptScore W2154798443C134018914 @default.
• W2154798443 hasConceptScore W2154798443C164705383 @default.
• W2154798443 hasConceptScore W2154798443C188816634 @default.
• W2154798443 hasConceptScore W2154798443C198710026 @default.
• W2154798443 hasConceptScore W2154798443C2777693730 @default.
• W2154798443 hasConceptScore W2154798443C2778402494 @default.
• W2154798443 hasConceptScore W2154798443C2779838083 @default.
• W2154798443 hasConceptScore W2154798443C2780259554 @default.
• W2154798443 hasConceptScore W2154798443C2780578515 @default.
• W2154798443 hasConceptScore W2154798443C511355011 @default.
• W2154798443 hasConceptScore W2154798443C555293320 @default.

• next